RUMI Scientific announces Receipt of Two-Year Phase II SBIR Award totaling $1.9 Million to Accelerate Discovery and Development of Novel Therapeutic Candidates for the Treatment of Autism NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- RUMI Scientific, Inc. (“RUMI”) a developer of therapies for rare and neurodegenerative diseases using its high throughput organoid phenotypic screening...

Rumi Scientific Announces Partnership with X-Chem for Development of Lead Candidate in Huntington’s Disease NEW YORK, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Rumi Scientific (“Rumi”), a developer of therapies for rare and neurodegenerative diseases using its high throughput organoid phenotypic screening...

Rumi Scientific Announces Data Demonstrating Disease Modifying Effect of BRD9 Inhibition in a Huntington’s Disease Animal Model NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- Rumi Scientific (“Rumi”), a developer of therapies for rare and neurodegenerative diseases discovered using its high throughput organoid phenotypic...

Rumi Scientific Appoints Allen A. Fienberg, Ph.D., as Chief Executive Officer and Chairman of the Board of Directors NEW YORK, March 30, 2023 (GLOBE NEWSWIRE) -- Rumi Scientific (“Rumi”), a developer of therapies for rare and neurodegenerative diseases discovered using its high throughput organoid phenotypic...